Maravai Lifesciences Holdings, INC 10-Q quarterly reports

Maravai LifeSciences Holdings, Inc. reported a significant revenue decrease and negative Adjusted EBITDA for Q3 and the first nine months of 2025, driven by a lack of high-volume vaccine program orders and a challenging R&D funding environment.

Maravai LifeSciences reported a significant decline in revenue and a substantial net loss for Q2 2025, alongside a major workforce reduction and goodwill impairments.

Maravai LifeSciences experienced a significant drop in revenue and reported a net loss for Q1 2025, primarily due to decreased demand for CleanCap used in commercial phase vaccine programs and lower demand for research and discovery products.

Maravai LifeSciences reported its Q3 2024 results, which included a significant goodwill impairment charge and a decrease in revenue, particularly in its Nucleic Acid Production segment.

Maravai LifeSciences reported a revenue increase in Q2 2024, but also a net loss, reflecting ongoing market challenges and strategic adjustments.

Maravai LifeSciences experienced a decrease in revenue during the first quarter of 2024, primarily due to reduced demand in its Nucleic Acid Production segment.